ARAdria Rose

Adria Rose

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adria Rose has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Costanza Di Chiara

    Division of Pediatric Infectious Diseases, Department for Women’s and Children’s Health, University of Padua, Padua, Italy

    2 shared publications
  • Shaun K. Morris

    Child Health Evaluative Sciences, The Hospital for Sick Children Research Institute, Toronto, ON, Canada; Division of Infectious Diseases, The Hospital for Sick Children, Toronto, ON, Canada; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

    2 shared publications
  • Adamos Hadjipanayis

    Affiliation Medical School, European University of Cyprus, Nicosia, Cyprus

    1 shared publication
  • Alfredo Tagarro

    Affiliations Paediatrics Department, Hospital Universitario Infanta Sofía, Paediatrics Research Group, Universidad Europea de Madrid, Madrid, Spain, Fundación de Investigación Biomédica Hospital 12 de Octubre, Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain, Fundación para la Investigación Biomédica Hospital Infanta Sofía y del Henares, Madrid, Spain

    1 shared publication
  • Andrea Lo Vecchio

    Affiliation Department of Translational Medical Science - Section of Paediatrics, University of Naples Federico II, Naples, Italy

    1 shared publication
  • Anna Cantarutti

    Affiliation Laboratory of Healthcare Research and Pharmacoepidemiology, Division of Biostatistics, Epidemiology and Public Health, Department of Statistic and Quantitative Methods, University of Milano-Bicocca, Milano, Italy

    1 shared publication

Latest Publications

  • Open Access

    Pediatricians’ attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey

    by Costanza Di Chiara, Pierre-Philippe Piché-Renaud, Vera Rigamonti, Anna Cantarutti, Cristina Calvo, Irene Rivero Calle, Antoni Soriano-Arandes, Carlo Giaquinto, Luigi Cantarutti, Daniele Donà, et al.

    Objective: Nirsevimab and the maternal vaccination in pregnancy are newly introduced prevention strategies against respiratory syncytial virus (RSV). This study evaluated pediatricians’ knowledge, attitudes, and barriers to RSV immunization in Italy and Cyprus/Greece, where nirsevimab had not yet been implemented, and in Spain, where it was introduced in 2023/2024. Methods: A survey was distributed to pediatricians across Spain, Italy, and Cyprus/Greece in July-August/2024. Occupational characteristics, and knowledge, attitudes and practices toward palivizumab, nirsevimab, and the maternal vaccine were collected. Of 578 respondents (response rate = 19.3%), 50% were from Spain, 40% from Italy, and 10% from Cyprus/Greece. As 90% of responses came from Spain and Italy, the main analysis focused on these two countries. Descriptive and univariate analyses (Chi-square or Fisher’s exact tests) were conducted. Results: Respondents included pediatricians from community (51.7%), tertiary (30.4%), and primary/secondary care (17.9%) settings. Pediatricians were generally aware of RSV risk factors, without differences across countries. However, 245 (55.9%) and 375 (86.0%) participants reported average-to-low knowledge of nirsevimab and the maternal vaccine, respectively, with differences across countries (p = 0.002). Despite limited knowledge, 311 (85.9%) pediatricians were willing to administer nirsevimab, and 319 (92.2%) supported its use for all infants. Nirsevimab administration’s barriers, including unfamiliarity and logistical challenges, were cited by 69 (20.0%) pediatricians. Regarding immunization preferences, 165 (47.4%) pediatricians were very likely to support the maternal vaccine over nirsevimab. Conclusions: While pediatricians support RSV immunization, knowledge gaps and logistical barriers may hinder early-stage implementation. Optimizing education on RSV immunization will be crucial to improve uptake and prevention strategies.

  • Open Access

    Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross‐Sectional Study

    by Adria Rose, Rohini R. Datta, Costanza Di Chiara, Pierre‐Philippe Piché‐Renaud, Shaun K. Morris

    Introduction: New RSV prevention products show strong potential, but their success depends on wide acceptance and use. We assessed Ontario pediatricians' knowledge and attitudes about these products before their introduction to highlight opportunities and barriers. Methods: In March−April 2024, Pediatricians Alliance of Ontario newsletter subscribers ( n = 1566) were invited to complete an online survey on RSV knowledge and attitudes. Descriptive analyses with a complete‐case approach assessed responses. Results: Of 117 responses (7% response rate), we retained 104 confirmed as from pediatricians with complete demographic data, including 81% (84/104) general pediatricians and 19% (20/104) subspecialists. Most worked in primary care (40%; 42/104), community hospitals (32%; 33/104), and urban centers (63%; 65/104), and had ≥ 10 years' experience (81%; 83/104). They had high awareness of provincial recommendations (91%; 94/103) and knowledge of severe RSV disease risk factors (Figure 2). While 83% (82/99) always recommended palivizumab to eligible patients, only 34% (34/99) reported that all eligible patients always received it. Over 90% were likely to recommend nirsevimab (91%; 89/98), but 66% (65/98) expected to administer it. Top anticipated barriers included the introduction of a new product (69%; 25/36) and concern for adverse effects (69%; 41/59). The likelihood of recommending a maternal vaccine over nirsevimab was 45% (44/98), while 44% (43/98) were neutral. Conclusion: Ontario pediatricians were knowledgeable and supportive of RSV prevention products. However, they have experienced barriers with palivizumab, and they anticipated barriers with nirsevimab and the maternal RSV vaccine. As other jurisdictions look to implement new RSV prevention products, acknowledging and addressing anticipated barriers may promote acceptance and use.